摘要
目的:探讨瑞舒伐他汀对高血压病并血脂异常患者高敏C-反应蛋白(hs-CRP)及胰岛素抵抗(IR)的影响。方法:选取高血压病并血脂异常患者100例,随机分为试验组及对照组,每组50例,均予降压治疗,试验组加用瑞舒伐他汀10mg/d,治疗时间为8周。另选取年龄、性别等相匹配的50例正常体检者作为健康组。观察治疗前后血压、血脂、血糖、hs-CRP、胰岛素抵抗指数(HOMA-IR)等指标变化。结果:试验组及对照组治疗前血清hs-CRP、HOMA-IR、血压、总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)水平均高于健康组(均P<0.05),而高密度脂蛋白胆固醇(HDL-C)低于健康组(P<0.05);相关分析示hs-CRP与HOMA-IR呈正相关(r=0.527,P<0.05)。试验组治疗8周后,与治疗前相比血压、血清hs-CRP、HOMA-IR、血压、TC、TG、LDL-C水平均明显下降(均P<0.05),HDL-C水平升高(P<0.05),BMI差异无统计学意义;对照组与治疗前相比,血压明显下降(P<0.01),余指标治疗前后差异无统计学意义;两组治疗后TC、LDL-C、HDL-C、HOMA-IR及hs-CRP水平比较差异有统计学意义(均P<0.05)。结论:瑞舒伐他汀治疗高血压病并血脂异常患者,调脂同时降低HOMA-IR及血清hs-CRP水平,有抗炎及改善IR的作用。
Objective：To study the effects of rosuvastatin on high-sensitivity C-reactive protein（hs-CRP）and insulin resistance（IR）in patients with hypertension and hyperlipidemia.Method：All 100patients with hypertension and hyperlipidemia were randomly divided into treatment group（n=50）and control group（n=50）.Both groups were treated with antihypertensive treatment,and treatment group was additionally treated with rosuvastatin（10mg/d）for 8weeks.Other 50normal subjects whose age,gender were matched were selected as healthy group.The changes of blood pressure,blood lipids,FPG,hs-CRP and insulin resistance index（HOMA-IR）in all were measured before and after treatment.Result：Levels of serum hs-CRP,HOMA-IR,blood pressure,total cholesterol（TC）,triglyeride（TG）and low density lipoprotein-cholesterol（LDL-C）were significantly higher in treatment group and control group than those in healthy group（all P0.05）,whereas high density lipoproteincholesterol（HDL-C）was lower（P0.05）.Pearson linear correlation analysis showed that hs-CRP was positively correlated with HOMA-IR（r=0.527,P0.05）.Levels of serum hs-CRP,HOMA-IR,blood pressure,TC, TG and LDL-C decreased significantly in treatment group after 8weeks of treatment（all P0.05）,Levels of HDL-C increased significangtly（P 0.05）,BMI had no significant difference.While blood pressure was decreased（P0.01）and other indexes were not found significant differenc in control group.The comparison of TC,LDL-C,HDL-C,HOMA-IR and hs-CRP between two groups were significantly different after the treatment（all P0.05）.Conclusion：The treatment of rosuvastatin in patients with hypertension and hyperlipidemia can not only regulate the levels of blood lipids,but also decrease the serum hs-CRP and HOMA-IR,acting as anti-inflammatory and improving IR.
出处
《临床心血管病杂志》
CAS
CSCD
北大核心
2014年第2期150-152,共3页
Journal of Clinical Cardiology
关键词
高血压
血脂异常
瑞舒伐他汀
高敏C-反应蛋白
胰岛素抵抗
hypertension
hyperlipidemia
rosuvastatin
high-sensitivity c-reactive protein
insulin resistance
